Cargando…

Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial

BACKGROUND: Symptom severity is the largest factor in determining subjective health in COPD. Symptoms (eg, chronic cough, dyspnea) are associated with decreased health-related quality of life (HRQoL). We evaluated the impact of arformoterol on HRQoL in COPD patients, measured by St George’s Respirat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donohue, James F, Bollu, Vamsi K, Stull, Donald E, Nelson, Lauren M, Williams, Valerie SL, Stensland, Michael D, Hanania, Nicola A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5804733/ https://www.ncbi.nlm.nih.gov/pubmed/29440887 http://dx.doi.org/10.2147/COPD.S141729

Ejemplares similares

One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD
por: Donohue, James F., et al.
Publicado: (2014)

Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol
por: Ganapathy, Vaidyanathan, et al.
Publicado: (2017)

Role of arformoterol in the management of COPD
por: King, Paul
Publicado: (2008)

Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD
por: Bollu, Vamsi, et al.
Publicado: (2013)

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)
por: Donohue, James F., et al.
Publicado: (2019)

A comparative study of efficacy and safety of arformoterol and salbutamol nebulization as rescue therapy in acute non-severe asthma
por: Das, Sibes K., et al.
Publicado: (2011)

Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment
por: Celli, Bartolome R, et al.
Publicado: (2019)

Targeting IL-5 in COPD
por: Narendra, Dharani K, et al.
Publicado: (2019)

Optimizing safety of COPD treatments: role of the nurse practitioner
por: Spencer, Pamela, et al.
Publicado: (2013)

52 Procedures in 52 Weeks: An Innovative Curriculum for Emergency Medicine Residents
por: Walsh, Ryan, et al.
Publicado: (2017)

Revisiting the Use of Antibiotics to Prevent COPD Exacerbation: Is Doxycycline the Answer?
por: Adrish, Muhammad, et al.
Publicado: (2023)

Association of Systemic Inflammation with Depressive Symptoms in Individuals with COPD
por: Strollo, Hilary C, et al.
Publicado: (2021)

The Saudi guidelines for chronic obstructive pulmonary disease: A fresh “Real-World” approach to COPD
por: Hanania, Nicola A.
Publicado: (2014)

Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD
por: Hanania, Nicola A, et al.
Publicado: (2018)

Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)
por: Yang, Ting, et al.
Publicado: (2023)

Real-World Safety and Efficacy of Glycopyrronium Bromide in Japanese Patients with COPD: A 52-Week Post-Marketing Surveillance
por: Kato, Chihiro, et al.
Publicado: (2022)

The role of combination therapy with corticosteroids and long-acting β(2)-agonists in the prevention of exacerbations in COPD
por: Cazzola, Mario, et al.
Publicado: (2006)

Novel Anti-Inflammatory Approaches to COPD
por: Cazzola, Mario, et al.
Publicado: (2023)

Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities
por: Matera, Maria Gabriella, et al.
Publicado: (2023)

Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study
por: Kerwin, Edward M., et al.
Publicado: (2019)

Treatment patterns in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)
por: Yang, Ting, et al.
Publicado: (2023)

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
por: Hanania, Nicola A, et al.
Publicado: (2011)

The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study
por: Yataba, Ikuko, et al.
Publicado: (2016)

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD
por: Doherty, Dennis E, et al.
Publicado: (2012)

Budesonide/formoterol combination in COPD: a US perspective
por: Sharafkhaneh, Amir, et al.
Publicado: (2010)

PS155. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies
por: Nelson, Craig, et al.
Publicado: (2016)

Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Creative 52: weekly projects to invigorate your photography portfolio
por: Adler, Lindsay
Publicado: (2014)

DNA methylation changes in infants between 6 and 52 weeks
por: Wikenius, Ellen, et al.
Publicado: (2019)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Treating COPD Patients with Inhaled Medications in the Era of COVID-19 and Beyond: Options and Rationales for Patients at Home
por: Ari, Arzu, et al.
Publicado: (2021)

Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial
por: Tashkin, Donald P, et al.
Publicado: (2012)

A Year with Peter Drucker - 52 Weeks of Coaching for Leadership Effectiveness
por: Maciariello, Joseph
Publicado: (2014)

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
por: Ailani, Jessica, et al.
Publicado: (2020)

Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study
por: Higuchi, Teruhiko, et al.
Publicado: (2021)

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
por: Buse, John B., et al.
Publicado: (2010)

Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52
por: Johnson, Travis, et al.
Publicado: (2023)

Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
por: Umezawa, Yoshinori, et al.
Publicado: (2021)

Risankizumab shows high efficacy and maintenance in improvement of response until week 52
por: Mastorino, Luca, et al.
Publicado: (2022)

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks
por: Birring, Surinder S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m2vd1ls3nad5s3qg402fpsl1fd